In vitro activity of BU-2313B against anaerobic bacteria.
The antimicrobial efficacy of BU-2313B, a new antibiotic, was evaluated in comparison with clindamycin, chloramphenicol and cefoxitin against 265 clinical anaerobic isolates. BU-2313B inhibited 88% of 66 isolates of Bacteroides fragilis tested at 2 micrograms/ml, whereas clindamycin, chloramphenicol and cefoxitin inhibited 98, 97 and 92% of them at 2, 8 and 16 micrograms/ml, respectively. BU-2313B was severalfold more effective than chloramphenicol and cefoxitin, but it was eight times less effective than clindamycin.
D000617:Aminoglycosides; D000693:Anaerobiosis; D000900:Anti-Bacterial Agents / Q000031:analogs & derivatives / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002440:Cefoxitin / Q000494:pharmacology; D002701:Chloramphenicol / Q000494:pharmacology; D002981:Clindamycin / Q000494:pharmacology; D008826:Microbial Sensitivity Tests
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002981:Clindamycin; D002701:Chloramphenicol; C025513:BU-2313 B; C100307:streptolydigin; D002440:Cefoxitin